Key result
Prior cancer therapy-related cardiac dysfunction in breast cancer survivors links to ~38% higher ventricular-arterial uncoupling.
Why the study?
Ventricular-arterial coupling and myocardial work can assess left ventricular-arterial interactions, but their relationship with cancer-therapy-related cardiac dysfunction in breast cancer survivors needed evaluation.
Does a history of cancer-therapy-related cardiac dysfunction alter ventricular-arterial coupling and myocardial work in breast cancer survivors?
Cross-Sectional (n=57)
No
Does a history of cancer-therapy-related cardiac dysfunction alter ventricular-arterial coupling and myocardial work in breast cancer survivors?
Answers are grounded in this paper and cite their sources.
Cancer-therapy-related cardiac dysfunction is associated with ventricular-arterial uncoupling in breast cancer survivors, driven by increased arterial load, which correlates with impaired cardiorespiratory fitness.
Aims Ventricular–arterial (VA) coupling and myocardial work can assess the interaction between the left ventricle and the arterial system and provide insight into cancer-therapy-related cardiac dysfunction (CTRCD). This study assessed the relationship between VA coupling and myocardial work indices with CTRCD in breast cancer (BC) survivors. Methods and results In this cross-sectional case–control study, 42 human epidermal growth factor receptor 2-positive BC survivors [22 with a history of CTRCD (TOX), 20 without CTRCD (NOTOX)] and 15 age-matched healthy controls (HC) prospectively underwent echocardiography and cardiopulmonary exercise testing. VA coupling measures were arterial elastance (Ea) and end-systolic elastance (Ees), with increased Ea/Ees indicating ventricular–arterial uncoupling. Myocardial work measures included global work index (GWI), global constructive work (GCW), global wasted work (GWW), and global work efficiency (GWE). Linear regression models assessed associations between VA coupling and myocardial work indices with cardiorespiratory fitness, measured by peak oxygen consumption (VO2peak). Ea and Ea/Ees were elevated in TOX [Ea: 2.00 (interquartile range (IQR), 1.83–2.25) mmHg/mL, P = 0.006; Ea/Ees: 1.48 (1.05–1.66), P = 0.002], but not NOTOX [Ea: 1.68 (1.36–1.95) mmHg/mL, P = 0.8]; [Ea/Ees: 1.15 (1.03–1.28), P = 0.2] participants, compared to HC [Ea, 1.65 (1.50–1.73) mmHg/mL; Ea/Ees, 1.07 (0.89–1.19)]. GWW was increased and GWE was reduced in TOX [GWW: 86 (59–132) mmHg%, P = 0.009; GWE: 95 (94–96) %, P = 0.003] but not NOTOX [GWW: 64 (44–94) mmHg%, P = 0.3; GWE: 96 (96–97) %, P = 0.003] participants, compared to HC [GWW: 46 (38–60) mmHg%; GWE: 97 (97–98) %]. Higher Ea (β=−0.16, P = 0.005) was associated with impaired VO2peak in BC survivors. Conclusion CTRCD is associated with VA uncoupling in BC survivors, the mechanism of which may be increased arterial load. Studies to evaluate whether reducing arterial load can mitigate VA uncoupling are needed.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2025) conducted a cross-sectional in Cancer therapy-related cardiac dysfunction in HER2-positive breast cancer survivors (n=57). History of cancer therapy-related cardiac dysfunction (CTRCD) vs. Breast cancer survivors without CTRCD and healthy controls was evaluated on Ventricular-arterial coupling (Ea/Ees ratio) (p=0.002). A history of cancer therapy-related cardiac dysfunction in breast cancer survivors was associated with significantly higher ventricular-arterial uncoupling compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: